Trials that use: Hazard ratio
New to this method? Read the tutorial →
334 results
- HPTN 052Independent statistical analysis of HPTN 052, a randomized phase 3 trial evaluating early versus delayed antiretroviral therapy and linked and all partner HIV infection rates.
- HPTN 083Independent statistical analysis of HPTN 083, a randomized phase 2/3 trial comparing injectable cabotegravir with TDF/FTC for HIV pre-exposure prophylaxis in HIV-uninfected men and transgender women who have sex with men.
- HVTN 505Complete statistical analysis of HVTN 505, a randomized phase 2 trial of HIV-1 DNA plasmid and recombinant adenoviral vector vaccines in HIV-uninfected participants, including trial design, endpoints, Cox survival analyses, safety, and…
- HVTN 702Independent statistical analysis of HVTN 702, a randomized phase 2/3 HIV vaccine prevention trial evaluating ALVAC-HIV and bivalent subtype C gp120/MF59 versus placebo, including time-to-event methods, hazard ratios, confidence intervals, safety, and…
- IBCSG 23-01Independent statistical analysis of IBCSG 23-01, a randomized trial of axillary lymph node dissection versus no axillary lymph node dissection in women with node-negative breast cancer and sentinel lymph node micrometastases.
- ICARIA-MMIndependent statistical analysis of the phase 3 ICARIA-MM trial comparing isatuximab, pomalidomide, and dexamethasone with pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma.
- IMblaze370Independent statistical analysis of IMblaze370, a randomized phase 3 trial comparing cobimetinib plus atezolizumab and atezolizumab monotherapy with regorafenib in metastatic colorectal adenocarcinoma.
- IMbrave050Independent statistical analysis of IMbrave050, a randomized phase 3 trial of atezolizumab plus bevacizumab versus active surveillance as adjuvant therapy in hepatocellular carcinoma at high risk of recurrence after surgical resection or…
- IMpassion130Complete statistical analysis of IMpassion130, a randomized phase 3 trial of atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated metastatic triple-negative breast cancer.
- IMpassion131Independent statistical analysis of IMpassion131, a randomized phase 3 trial of atezolizumab plus paclitaxel versus placebo plus paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer.
- IMpower010Independent statistical analysis of IMpower010, the randomized phase 3 trial of atezolizumab versus best supportive care following chemotherapy in non-small cell lung cancer, including disease-free survival, time-to-event methodology, confidence intervals, and interpretation.
- IMpower132Independent statistical analysis of IMpower132, a phase 3 randomized trial of atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in chemotherapy-naive participants with stage IV non-squamous non-small cell lung cancer.
- IMpower133Independent statistical analysis of IMpower133 (NCT02763579), a randomized phase 3 trial of atezolizumab plus carboplatin and etoposide versus placebo plus carboplatin and etoposide in untreated extensive-stage small cell lung cancer.
- IMvigor010Independent statistical analysis of IMvigor010, the randomized phase 3 study of atezolizumab versus observation as adjuvant therapy after surgical resection for high-risk muscle-invasive urothelial carcinoma.
- IMvigor130Independent statistical analysis of IMvigor130, a randomized phase 3 trial of atezolizumab with platinum-based chemotherapy or as monotherapy in untreated locally advanced or metastatic urothelial carcinoma.
- IMvigor211Independent statistical analysis of the phase 3 IMvigor211 trial of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer, including overall survival, hazard ratios, confidence intervals, and…
- INAVO120Independent statistical analysis of the INAVO120 trial of inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.
- INBUILDIndependent statistical analysis of the INBUILD phase 3 trial of nintedanib in patients with progressive fibrosing interstitial lung disease, including FVC decline, longitudinal modeling, time-to-event endpoints, logistic regression, safety, and interpretation.
- iPrExIndependent statistical analysis of the randomized phase 3 iPrEx trial of daily TDF/FTC versus placebo for HIV prevention in men, including primary efficacy and safety endpoints, secondary analyses, statistical methods, and interpretation.
- ISABELA 1Independent statistical analysis of ISABELA 1 (NCT03711162), a randomized phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis, including FVC decline, disease progression, hospitalization, mixed-effects models, logistic regression, Cox models, and safety.
- ISABELA 2Complete statistical analysis of the ISABELA 2 phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis, including trial design, FVC decline, disease progression, hospitalization, survival endpoints, safety, statistical methodology, and interpretation.
- ISCHEMIA-CKDIndependent statistical analysis of ISCHEMIA-CKD, a randomized phase 4 trial comparing invasive and conservative strategies in patients with cardiovascular and kidney disease. Includes trial design, time-to-event endpoints, hazard-ratio interpretation, reported results, safety,…
- JAVELIN Bladder 100A detailed statistical analysis of the randomized phase 3 JAVELIN Bladder 100 trial of avelumab plus best supportive care versus best supportive care in patients with urothelial cancer, including trial design, time-to-event…
- JAVELIN Head and Neck 100Independent statistical analysis of JAVELIN Head and Neck 100, a randomized phase 3 trial comparing avelumab plus standard of care chemoradiotherapy with placebo plus standard of care chemoradiotherapy in squamous cell carcinoma…
- JAVELIN Ovarian 100Independent statistical analysis of JAVELIN Ovarian 100, the phase 3 trial of avelumab-based strategies in previously untreated epithelial ovarian cancer, including progression-free survival, overall survival, statistical methodology, safety, and interpretation.
- JAVELIN Renal 101Complete statistical analysis of JAVELIN Renal 101, the randomized phase 3 trial of avelumab plus axitinib versus sunitinib in advanced renal cell cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing,…
- KATHERINEIndependent statistical analysis of KATHERINE, the randomized phase 3 trial of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer and residual tumor following preoperative therapy.
- KEYNOTE-006Independent statistical analysis of KEYNOTE-006, a randomized phase 3 trial comparing two pembrolizumab dosing schedules with ipilimumab in participants with advanced melanoma.
- KEYNOTE-010Independent statistical analysis of KEYNOTE-010, including its randomized phase 2/3 design, overall survival, progression-free survival, response, safety, statistical methods, and interpretation.
- KEYNOTE-024Independent statistical analysis of KEYNOTE-024 (NCT02142738), including randomized trial design, progression-free survival, overall survival, objective response rate, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-040Independent statistical analysis of KEYNOTE-040, a randomized phase 3 trial of pembrolizumab versus standard treatment for recurrent or metastatic head and neck squamous cell cancer, including overall survival, progression-free survival, response, statistical…
- KEYNOTE-045Independent statistical analysis of KEYNOTE-045, a randomized phase 3 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in advanced urothelial cancer, including primary and secondary endpoint results and statistical interpretation.
- KEYNOTE-054Independent statistical analysis of KEYNOTE-054, a randomized phase 3 trial of pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-062Independent statistical analysis of KEYNOTE-062, a randomized phase 3 trial of pembrolizumab monotherapy and pembrolizumab plus standard chemotherapy in advanced gastric adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- KEYNOTE-119Independent statistical analysis of KEYNOTE-119, a randomized phase 3 trial comparing single-agent pembrolizumab with single-agent chemotherapy in metastatic triple negative breast cancer, including overall survival, response, progression-free survival, statistical methodology, and interpretation.
- KEYNOTE-177Independent statistical analysis of KEYNOTE-177, the randomized phase 3 trial of pembrolizumab versus standard of care in participants with MSI-H or dMMR stage IV colorectal carcinoma, covering PFS, overall survival, response, statistical…
- KEYNOTE-189Independent statistical analysis of KEYNOTE-189 (NCT02578680), a randomized phase 3 trial evaluating pembrolizumab with pemetrexed-platinum chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-355Independent statistical analysis of KEYNOTE-355, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- KEYNOTE-361Independent statistical analysis of KEYNOTE-361, the randomized phase 3 trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma, including primary and secondary endpoint analyses, statistical methods,…
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- KEYNOTE-426Independent statistical analysis of KEYNOTE-426, the randomized phase 3 trial of pembrolizumab plus axitinib versus sunitinib monotherapy in renal cell carcinoma, including primary survival endpoints, response outcomes, statistical methodology, and interpretation.
- KEYNOTE-564Independent statistical analysis of KEYNOTE-564, a randomized phase 3 trial of pembrolizumab versus placebo in the adjuvant treatment of renal cell carcinoma after nephrectomy, including disease-free survival, trial design, statistical methodology, and…
- KEYNOTE-598Independent statistical analysis of KEYNOTE-598, a randomized phase 3 trial of pembrolizumab with ipilimumab versus pembrolizumab with placebo in untreated metastatic non-small cell lung cancer. Includes overall survival, progression-free survival, response, quality…
- KEYNOTE-671Independent statistical analysis of KEYNOTE-671, a randomized phase 3 trial of pembrolizumab with platinum-doublet chemotherapy as neoadjuvant/adjuvant therapy for resectable stage II, IIIA, and resectable IIIB non-small cell lung cancer.
- KEYNOTE-716Independent statistical analysis of KEYNOTE-716, a randomized phase 3 trial of pembrolizumab versus placebo in resected high-risk stage II melanoma, including trial design, recurrence-free survival, safety, statistical methodology, and interpretation.
- KEYNOTE-775Independent statistical analysis of KEYNOTE-775, evaluating lenvatinib plus pembrolizumab versus treatment of physician's choice in advanced endometrial cancer, with detailed interpretation of PFS, OS, response, quality-of-life, and statistical methods.
- KEYNOTE-811Independent statistical analysis of KEYNOTE-811, a randomized phase 3 trial of pembrolizumab plus trastuzumab and chemotherapy versus standard of care in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
- KEYNOTE-826Independent statistical analysis of KEYNOTE-826, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer.
- KEYNOTE-859Independent statistical analysis of KEYNOTE-859, a randomized phase 3 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric or gastroesophageal junction adenocarcinoma, including overall survival, progression-free survival, objective response rate,…